GE Healthcare's Manganese Contrast Agent Receives FDA Fast Track Designation
What happened
GE Healthcare announced that its investigational manganese-based MRI contrast agent, mangaciclanol, advanced into Phase 3 trials after Phase 2 results met the primary endpoint. The agent was well tolerated in Phase 2 and received FDA Fast Track designation. If approved, mangaciclanol could serve as an alternative to gadolinium-based contrast agents.
From finanznachrichten.de
Why it matters
The agent is being developed to address concerns regarding gadolinium retention, supply chain resiliency, and environmental impact. Currently, approximately 65 million gadolinium-enhanced MRI procedures are performed each year. This advancement could shift the market for MRI contrast agents.
From finanznachrichten.de
Who's involved
- Mayo ClinicPartnered with GE Healthcare on clinical trials and technology adoption.
- GE HealthcareDeveloping the manganese-based contrast agent, mangaciclanol.
- manganeseCore material component utilized in the contrast agent.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- gadoliniumSpeculative
Gadolinium might face reduced demand and market share as a new alternative becomes available.
- manganeseSpeculative
Manganese could experience increased demand as the development of manganese-based agents accelerates.
Keep exploring
The entities involved
-
Mayo Clinic
medical practice and medical research group based in Rochester, Minnesota, United States
-
GE Healthcare
company
-
manganese
chemical element, symbol Mn and atomic number 25
Nothing else this week.